Regeneron AI Stock Analysis
Want to see REGN full AI Analyst Report?
Regeneron (REGN) AI Stock Analysis
Regeneron
(NASDAQ:REGN)
REGN scores well primarily due to strong financial quality (high margins, improving growth, and very low leverage) and a notably positive earnings update featuring rapid revenue/EPS growth and strong pipeline progress. The score is tempered by overbought technical conditions and only moderate valuation support given a low dividend yield, plus product-specific headwinds around legacy EYLEA declines and pricing pressure.
Regeneron Key Performance Indicators (KPIs)
Revenue by SegmentShows how revenue is distributed across different business units, highlighting which areas are driving growth and which might need strategic adjustments.
Collaboration revenue has emerged as the primary growth driver, with a clear step‑up tied to Sanofi profit-share dynamics that will materially boost reported collaboration going forward and underpin cash generation/repurchases. Net product sales show durable momentum fueled by Dupixent scale and rapid EYLEA HD adoption, but legacy EYLEA declines and biosimilar competition create near-term headwinds and make timing of syringe approvals and manufacturing normalization key execution risks. “Other” remains small and volatile—worth watching but not a primary earnings lever.
Regeneron (REGN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $98.82B
- Dividend Yield
- 0.39%
- Average Volume (3M)
- 793.62K
- Price to Earnings (P/E)
- 20.4
- Beta (1Y)
- 0.55
- Revenue Growth
- 18.59%
- EPS Growth
- 8.14%
- Country
- US
- Employees
- 15,410
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Regeneron Business Overview & Revenue Model
Company Description
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA,...
How the Company Makes Money
Regeneron generates revenue primarily from (1) net product sales of medicines it sells directly and (2) collaboration and other revenues from strategic partnerships (most notably with Sanofi and Bayer), plus (3) royalty and profit-sharing arrangement...
Regeneron Earnings Call Summary
The call was strongly positive, supported by 36% revenue growth, 70% earnings-per-share growth, record sales for Dupixent, EYLEA HD, and Libtayo, strong cash generation, an expanded Sanofi alliance, and substantial progress across a broad clinical pipeline. The principal challenges were declining EYLEA sales and demand, biosimilar and pricing pressure, modest lynozyfic growth in its current setting, a higher expected tax rate, and no anticipated Inmazeb revenue in the fourth quarter of 2026. Highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For the fourth quarter, EYLEA HD sequential growth is expected to be approximately 10%, partially offset by ongoing pricing pressure, while EYLEA sequential demand is expected to decline in the low- to mid-teens; full year EYLEA HD net sales growth is expected to be over 50% compared with 2025, full year share repurchases are expected to total approximately $3 billion, and 2027 R&D expense is expected to increase by a mid teens percentage compared with 2026, with 100 to 200 basis points of upward pressure on the 2027 effective tax rate relative to 2026. Regeneron does not anticipate recording any revenue in the fourth quarter of 2026 for Inmazeb and expects to supply additional treatment doses to the US government beginning in late 2027 through 2031; it also expects an FDA decision for cemdisiran in November, a European Commission decision in the second half of 27, pivotal results for the knee replacement factor 11 program starting next year, a potentially registrational POTS study in the first half of next year, and registrational studies of the olatorepatide and Praluent combination next year.
Regeneron Financial Statement Overview
Summary
High-quality fundamentals: strong profitability (TTM gross margin ~84.9%, EBIT margin ~33.6%), re-accelerating revenue growth (~8.8% TTM), and an exceptionally conservative balance sheet (debt-to-equity ~0.06). Offsetting factors are normalized margins/returns versus 2021–2022 peaks and softer near-term cash conversion (OCF and FCF below net income in TTM).
Income Statement
86Very PositiveBalance Sheet
92Very PositiveCash Flow
80Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.90B | 14.34B | 14.20B | 13.12B | 12.17B | 16.07B |
| Gross Profit | 14.49B | 12.24B | 12.23B | 10.87B | 10.47B | 13.35B |
| EBITDA | 6.25B | 5.82B | 5.32B | 4.69B | 5.26B | 9.67B |
| Net Income | 4.82B | 4.50B | 4.41B | 3.95B | 4.34B | 8.08B |
Balance Sheet | ||||||
| Total Assets | 44.41B | 40.56B | 37.76B | 33.08B | 29.21B | 25.43B |
| Cash, Cash Equivalents and Short-Term Investments | 9.30B | 8.61B | 9.01B | 10.84B | 7.74B | 5.69B |
| Total Debt | 2.71B | 2.71B | 2.70B | 2.70B | 2.70B | 2.70B |
| Total Liabilities | 10.91B | 9.30B | 8.41B | 7.11B | 6.55B | 6.67B |
| Stockholders Equity | 33.50B | 31.26B | 29.35B | 25.97B | 22.66B | 18.77B |
Cash Flow | ||||||
| Free Cash Flow | 3.83B | 4.08B | 3.66B | 3.88B | 4.42B | 6.53B |
| Operating Cash Flow | 4.85B | 4.98B | 4.42B | 4.59B | 5.01B | 7.08B |
| Investing Cash Flow | -589.40M | -629.10M | -2.47B | -3.19B | -3.78B | -5.38B |
| Financing Cash Flow | -3.10B | -3.72B | -2.20B | -1.79B | -1.01B | -1.01B |
Regeneron Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For REGN, the sentiment is Positive. The current price of 952.40 is above the 20-day moving average (MA) of 878.88, above the 50-day MA of 816.17, and above the 200-day MA of 745.84, indicating a bullish trend. The MACD of 42.96 indicates Negative momentum. The RSI at 68.37 is Neutral, neither overbought nor oversold. The STOCH value of 68.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for REGN.
Regeneron Risk Analysis
Regeneron disclosed 47 risk factors in its most recent earnings report. Regeneron reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksRegeneron Peers Comparison
Overall Rating
REGN81Outperform
ARGX76Outperform
INCY73Outperform
ALNY70Outperform
GMAB63Neutral
BMRN56Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | $98.82B | 20.35 | 15.07% | 0.39% | 18.59% | 8.14% | |
| 76Outperform | $60.89B | 45.50 | 16.86% | ― | 70.57% | 30.28% | |
| 73Outperform | $24.66B | 57.60 | 7.11% | ― | 24.88% | -65.67% | |
| 70Outperform | $22.11B | 8.10 | 159.72% | ― | 56.17% | 6459.20% | |
| 63Neutral | $30.47B | 42.80 | 12.26% | ― | 19.61% | -50.40% | |
| 56Neutral | $11.09B | -635.89 | -0.31% | ― | 19.76% | -103.57% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals | 952.40 | 230.76 | 31.98% | |
| ALNY | Alnylam Pharmaceuticals | 159.73 | -302.57 | -65.45% | |
| BMRN | Biomarin Pharmaceutical Inc. | 57.99 | 3.83 | 7.07% | |
| INCY | Incyte | 120.27 | 16.38 | 15.77% | |
| ARGX | Argenx | 950.95 | 32.42 | 3.53% | |
| GMAB | Genmab (Otc) | 51.57 | 21.25 | 70.09% |
Regeneron Corporate Events
Regeneron, Sanofi deepen antibody collaboration with expanded alliance
PositiveOn October 1, 2026, Regeneron and long-time partner Sanofi expanded their antibody collaboration through a Sixth Amendment to their Antibody License and Collaboration Agreement, adding four new long-acting, Regeneron-invented antibodies targeting IL-...
Regeneron Overhauls Executive Pay With Long-Term Performance Plan
PositiveOn September 24, 2026, Regeneron’s board approved one-time, performance-based share unit awards for CEO Leonard Schleifer and CSO George Yancopoulos, replacing their annual long‑term equity grants through 2036 and tying compensation to a 10‑year slat...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026
